Skip to main content

Table 1 Overview of longitudinal cohort data from Papua New Guinea and Thailand

From: Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses

 

Papua New Guinea (n = 504)

Thailand (n = 999)

Placebo arm (n = 257)

Primaquine arm (n = 247)

Gender (male)

49.8% (128)

48.6% (120)

46.2% (462)

Age (years)

7.5 (4.9, 10.4)

7.6 (4.8, 10.4)

23 (1, 82)

Bednet usage

93.4% (240)

93.1% (230)

88.8% (888)

Duration of follow-up (days)

224 (56, 231)

224 (42, 229)

369 (360, 378)

Proportion of data missing

12.3%

10.1%

8.3%

Any P. vivax infection by qPCR

69.6% (179)

27.9% (69)

11.9% (119)

Any P. vivax infection by LM

54.5% (140)

21.9% (54)

–

Number of P. vivax genotypes

2.2 (0, 12)

0.7 (0, 7)

0.3 (0, 11)

Any P. falciparum infection by qPCR

37.0% (95)

34.0% (84)

2.4% (24)

Any P. falciparum infection by LM

23.7% (61)

27.9% (69)

–

Number of P. falciparum genotypes

0.6 (0, 9)

0.5 (0, 6)

0.03 (0, 6)

Any fever

53.7% (138)

62.3% (154)

24.7% (247)

Any fever with qPCR+ P. vivax

10.1% (26)

4.0% (10)

2.1% (21)

Any fever with qPCR+ P. falciparum

9.7% (25)

16.6% (41)

0.3% (3)

  1. The data from PNG is for the period after the initial drug regimen. Missing data is defined as the proportion of samples scheduled in the study protocols missed. Data on age, numbers of genotypes detected during follow-up, and duration of follow-up are presented as mean and ranges. Light microscopy (LM) data was not available for the Thai samples